Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clincial and economic outcomes. Clin Ther. 2011;33(1):74–109.
Edelman SV, Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40(11):1425–32.
Ottawa Hospital Research Institute, University of Oxford. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) website. Available at: http://www.prisma-statement.org/PRISMAStatement/PRISMAStatement.aspx. Accessed Apr 8, 2019.
Wells GA, Shea B, O’Connel D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quailty of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed Apr 8, 2019.
Wei W, Pan C, Xie L, Baser O. Real-world insulin treatment persistence among patients with type 2 diabetes. Endocr Pract. 2014;20(1):52–61.
Leiter LA, Boras D, Woo VC. Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals. Can J Diabetes. 2014;38(1):38–44.
Wang L, Wei W, Miao R, Xie L, Baser O. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study. BMJ Open. 2013;3:e002348.
Ascher-Svanum H, Lage MJ, Perez-Nieves M, et al. Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014;5(1):225–42.
Perez-Nieves M, Ivanova JI, Hadjiyianni I, et al. Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey. Curr Med Res Opin. 2017;33(10):1833–42.
Linetzky B, Jiang D, Funnell MM, Curtis BH, Polonsky WH. Exploring the role of the patient-physician relationship on insulin adherence and clinical outcomes in type 2 diabetes: insights from the MOSAIc study. J Diabetes. 2017;9(6):596–605.
Egede LE, Gebregziabher M, Echols C, Lynch CP. Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother. 2014;48(5):562–70.
Osborn CY, Gonzalez JS. Measuring insulin adherence among adults with type 2 diabetes. J Behav Med. 2016;39(4):633–41.
DiBonaventura M, Wintfeld N, Huang J, Goren A. The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs. Patient Prefer Adherence. 2014;8:873–82.
Anderten H, Dippel FW, Kostev K. Early discontinuation and related treatment costs after initiation of basal insulin in type 2 diabetes patients: a German primary care database analysis. J Diabetes Sci Technol. 2015;9(3):644–50.
Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment. Value Health. 2015;18(2):198–205.
Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM. 2007;100(6):345–50.
Wu EQ, Zhou S, Yu A, et al. Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization. Endocr Pract. 2012;18(5):651–9.
Mashitani T, Hayashino Y, Okamura S, et al. Patient-reported adherence to insulin regimen is associated with glycemic control among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry in Tenri (DDCRT 3). Diabetes Res Clin Pract. 2013;100(2):189–94.
Sambamoorthi U, Garg R, Deb A, Fan T, Boss A. Persistence with rapid-acting insulin and its association with A1C level and severe hypoglycemia among elderly patients with type 2 diabetes. Curr Med Res Opin. 2017;33(7):1309–16.
Kindmalm L, Melander A, Nilsson JL. Refill adherence of antihyperglycaemic drugs related to glucose control (HbA1c) in patients with type 2 diabetes. Acta Diabetol. 2007;44(4):209–13.
Yavuz DG, Ozcan S, Deyneli O. Adherence to insulin treatment in insulin-naive type 2 diabetic patients initiated on different insulin regimens. Patient Prefer Adherence. 2015;9:1225–31.
Linetzky B, Curtis B, Frechtel G, et al. Challenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAIc study baseline data. Diabetol Metab Syndr. 2016;8:41.
Nishimura A, Harashima SI, Fukushige H, et al. A large difference in dose timing of basal insulin introduces risk of hypoglycemia and overweight: a cross-sectional study. Diabetes Ther. 2017;8(2):385–99.
Aikens JE, Piette JD. Longitudinal association between medication adherence and glycaemic control in type 2 diabetes. Diabet Med. 2013;30(3):338–44.
Hadjiyianni I, Desai U, Suzuki S, et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation: a retrospective database study among people with type 2 diabetes mellitus in Japan. Diabetes Ther. 2017;8(1):149–66.
Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948–62.
Kleinman NL, Schaneman JL, Lynch WD. The association of insulin medication possession ratio, use of insulin glargine, and health benefit costs in employees and spouses with type 2 diabetes. J Occup Environ Med. 2008;50(12):1386–93.
Chandran A, Bonafede MK, Nigam S, Saltiel-Berzin R, Hirsch LJ, Lahue BJ. Adherence to insulin pen therapy is associated with reduction in healthcare costs among patients with type 2 diabetes mellitus. Am Health Drug Benefits. 2015;8(3):148–58.
Perez-Nieves M, Kabul S, Desai U, et al. Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US. Curr Med Res Opin. 2016;32(4):669–80.
Kalirai S, Duan R, Liu D, Reed BL. Economic impact of treatment duration and persistence with basal insulin in previously insulin-naive users. J Manag Care Spec Pharm. 2017;23(3):327–36.
Lin J, Lingohr-Smith M, Fan T. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. Clinicoecon Outcomes Res. 2017;9:19–29.
Levin PA, Wei W, Zhou S, Xie L, Baser O. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. J Manag Care Spec Pharm. 2014;20(5):501–12.
Durden E, Lenhart G, Lopez-Gonzalez L, Hammer M, Langer J. Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States. J Med Econ. 2016;19(4):403–13.
Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32(4):341–55.
Carls GS, Tuttle E, Tan RD, et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1RA and DPP4 therapies in patients with type 2 diabetes. Diabetes Care. 2017;40(11):1469–78.
Buysschaert M, Preumont V, Oriot PR, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36(5):381–8.
Varanasi A, Chaudhuri A, Dhindsa S, et al. Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocr Pract. 2011;17(2):192–200.
Ivanyi T, Fovenyi J, Faludi P, et al. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary. Clin Ther. 2012;34(6):1301–13.
Chen YC, Lee CT, Lin BJ, Chang YY, Shi HY. Impact of pay-for-performance on mortality in diabetes patients in Taiwan: a population-based study. Medicine. 2016;95(27):e4197.
Polonsky WH, Fisher L, Hessler D, Edelman SV. Development of a new measure for assessing insulin delivery device satisfaction in patients with type 1 and type 2 diabetes. Diabetes Technol Ther. 2015;17(11):773–9.
Kokoszka A. Treatment adherence in patients with type 2 diabetes mellitus correlates with different coping styles, low perception of self-influence on disease, and depressive symptoms. Patient Prefer Adherence. 2017;11:587–95.
Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, et al. Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence. Obes Sci Pract. 2017;3(3):342–51.
Slabaugh SL, Bouchard JR, Li Y, Baltz JC, Meah YA, Moretz DC. Characteristics relating to adherence and persistence to basal insulin regimens among elderly insulin-naïve patients with type 2 diabetes: pre-filled pens versus vials/syringes. Adv Ther. 2015;32(12):1206–21.
Stephenson JJ, Raval AD, Kern DM, Bae JP. Non-adherence to basal insulin among patients with type 2 diabetes in a US managed care population: results from a patient survey. Diabetes Obes Metab. 2018;20(11):2700–4.
Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.
Tuchscherer RM, Thompson AM, Trujillo JM. Semaglutide: the newest once-weekly GLP-1 RA for type 2 diabetes. Ann Pharmacother. 2018;52(12):1224–32.
DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–811.
Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin. 2007;23(7):1493–507.
Robins J, Hernan M, Babette B. Marginal structural models and causal inference in epidemiology. Epidemiol. 2000;11(5):550–60.
Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiol. 2000;11(5):561–70.
Robins JM. Marginal structural models versus structural nested models as tools for causal inference. In: Halloran E, Berry D, editors. Statistical models in epidemiology: the environment and clinical trials. New York: Springer; 1999.
Li Q, Ganguly R, Ganz ML, Gamble C, Dang-Tan T. Real-world clinical effectiveness and cost savings of liraglutide versus sitagliptin in treating type 2 diabetes for 1 and 2 years. Diabetes Ther. 2018;9:1279–93.
National Institute for Health and Care Excellence (NICE). Medicines adherence: involving patients in decisions about prescribed medicines and support in adherence. Clinical guideline 2009. Available at: https://www.nice.org.uk/guidance/cg76/chapter/introduction. Accessed Apr 8, 2019.
Brown JB, Nichols GA, Glauber HS, Bakst A. Ten year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther. 1999;21(6):1045–57.
World Health Organization. Adherence to long-term therapy: evidence for action. 2003. Available at: http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed April 8, 2019.
Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;(11)CD000011.
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.
Marino AB, Cole SW, Nuzum DS. Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2014;71(3):223–6.
Choudhry N, Avorn J, Glynn RJ, et al., for the Post-Myocaridal Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. New Engl J Med. 2011;365(22):2088-97.
Kaiser Family Foundation. Public opinion on prescription drugs and their prices. Slide presentation. Available at: https://www.kff.org/slideshow/public-opinion-on-prescription-drugs-and-their-prices/. Accessed Apr 8, 2019.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Cont Clin Trials. 1989;10(4):407–15.
Wells G, Beaton D, Shea B, et al. Minimal clinically important differences: review of methods. J Rheumatol. 2001;28(2):406–12.